Identification of prognostic factors for postoperative recurrence-free survival in T2-stage renal cell carcinoma: a retrospective cohort study

肾细胞癌T2期患者术后无复发生存期预后因素的识别:一项回顾性队列研究

阅读:3

Abstract

BACKGROUND: T2-stage renal cell carcinoma (RCC) is associated with high postoperative recurrence risk and heterogeneous outcomes, but stage-specific prognostic factors remain insufficiently explored. This study aimed to systematically analyze the clinicopathological factors influencing postoperative recurrence-free survival (RFS) (defined as the time from surgical resection to the first occurrence of local recurrence, distant metastasis, or death from any cause) in patients with T2-stage RCC and explore reliable independent prognostic indicators for this specific subgroup. METHODS: We retrospectively collected clinicopathological data and follow-up records of T2-stage RCC patients who underwent surgery at the Second Hospital of Lanzhou University from January 2018 to December 2023. Postoperative RFS was the primary endpoint. The Kaplan-Meier method was used for survival analysis and survival curve plotting; univariate and multivariate Cox proportional hazards regression models were applied to identify independent prognostic factors. Internal stability of the identified prognostic factors was evaluated using bootstrap resampling (1,000 iterations) and Harrell's concordance index (C-index). RESULTS: A total of 182 patients were included (mean age: 55±13 years; median follow-up: 40 months). After rigorous variable screening (including collinearity elimination and biological independence assessment), five independent prognostic factors for postoperative RFS were identified: the aspartate transaminase to alanine transaminase ratio (AST/ALT ratio) [hazard ratio (HR) =3.295, 95% confidence interval (CI): 1.899-5.719, P<0.001], Fuhrman grade (HR =2.380, 95% CI: 1.412-4.012, P=0.001), systemic immune-inflammation index (SII) (HR =3.009, 95% CI: 1.567-5.776, P<0.001), sarcomatoid differentiation (HR =3.463, 95% CI: 1.981-6.054, P<0.001), and carbonic anhydrase IX (CAIX) (HR =5.425, 95% CI: 2.555-11.519, P<0.001). Internal validation showed a mean C-index of 0.835 (95% CI: 0.780-0.885), indicating good and stable discriminatory ability of the identified factors. CONCLUSIONS: The AST/ALT ratio, Fuhrman grade, SII, sarcomatoid differentiation, and CAIX are independent prognostic indicators for postoperative RFS in T2-stage RCC patients. These factors can facilitate accurate risk stratification and provide a scientific basis for formulating individualized follow-up and treatment strategies. Given the limitations of single-center retrospective design and small sample size, future large-scale prospective multicenter studies are needed to validate these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。